China opens regulatory data protection to foreign pharma, but gaps remain
New pharmaceutical regulatory data protection requirements in China eliminate earlier China-first launch requirements, giving foreign drugmakers equal access to up to six years of market exclusivity under most circumstances. The reform...To view the full article, register now.
Already a subscriber? Click here to view full article